Literature DB >> 33465158

K18-hACE2 mice develop respiratory disease resembling severe COVID-19.

Claude Kwe Yinda1, Julia R Port1, Trenton Bushmaker1, Irene Offei Owusu1, Jyothi N Purushotham1, Victoria A Avanzato1, Robert J Fischer1, Jonathan E Schulz1, Myndi G Holbrook1, Madison J Hebner1, Rebecca Rosenke2, Tina Thomas2, Andrea Marzi1, Sonja M Best1, Emmie de Wit1, Carl Shaia2, Neeltje van Doremalen1, Vincent J Munster1.   

Abstract

SARS-CoV-2 emerged in late 2019 and resulted in the ongoing COVID-19 pandemic. Several animal models have been rapidly developed that recapitulate the asymptomatic to moderate disease spectrum. Now, there is a direct need for additional small animal models to study the pathogenesis of severe COVID-19 and for fast-tracked medical countermeasure development. Here, we show that transgenic mice expressing the human SARS-CoV-2 receptor (angiotensin-converting enzyme 2 [hACE2]) under a cytokeratin 18 promoter (K18) are susceptible to SARS-CoV-2 and that infection resulted in a dose-dependent lethal disease course. After inoculation with either 104 TCID50 or 105 TCID50, the SARS-CoV-2 infection resulted in rapid weight loss in both groups and uniform lethality in the 105 TCID50 group. High levels of viral RNA shedding were observed from the upper and lower respiratory tract and intermittent shedding was observed from the intestinal tract. Inoculation with SARS-CoV-2 resulted in upper and lower respiratory tract infection with high infectious virus titers in nasal turbinates, trachea and lungs. The observed interstitial pneumonia and pulmonary pathology, with SARS-CoV-2 replication evident in pneumocytes, were similar to that reported in severe cases of COVID-19. SARS-CoV-2 infection resulted in macrophage and lymphocyte infiltration in the lungs and upregulation of Th1 and proinflammatory cytokines/chemokines. Extrapulmonary replication of SARS-CoV-2 was observed in the cerebral cortex and hippocampus of several animals at 7 DPI but not at 3 DPI. The rapid inflammatory response and observed pathology bears resemblance to COVID-19. Additionally, we demonstrate that a mild disease course can be simulated by low dose infection with 102 TCID50 SARS-CoV-2, resulting in minimal clinical manifestation and near uniform survival. Taken together, these data support future application of this model to studies of pathogenesis and medical countermeasure development.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33465158      PMCID: PMC7875348          DOI: 10.1371/journal.ppat.1009195

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  45 in total

1.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.

Authors:  Ling Mao; Huijuan Jin; Mengdie Wang; Yu Hu; Shengcai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Xiaoping Miao; Yanan Li; Bo Hu
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

Review 2.  The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome.

Authors:  Houli Wang; Sui Ma
Journal:  Am J Emerg Med       Date:  2008-07       Impact factor: 2.469

3.  Specific depletion of Ly6C(hi) inflammatory monocytes prevents immunopathology in experimental cerebral malaria.

Authors:  Beatrix Schumak; Katrin Klocke; Janina M Kuepper; Aindrila Biswas; Andrea Djie-Maletz; Andreas Limmer; Nico van Rooijen; Matthias Mack; Achim Hoerauf; Ildiko Rita Dunay
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

4.  Spectrum of chest computed tomographic (CT) findings in coronavirus disease-19 (COVID-19) patients in India.

Authors:  Arshed Hussain Parry; Abdul Haseeb Wani; Mudasira Yaseen; Khurshid Ahmad Dar; Naseer Ahmad Choh; Naseer Ahmad Khan; Naveed Nazir Shah; Majid Jehangir
Journal:  Eur J Radiol       Date:  2020-06-24       Impact factor: 3.528

5.  Could SARS-CoV-2-Induced Hyperinflammation Magnify the Severity of Coronavirus Disease (CoViD-19) Leading to Acute Respiratory Distress Syndrome?

Authors:  A S Smiline Girija; Esaki M Shankar; Marie Larsson
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

6.  Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19).

Authors:  Fang Jiang; Liehua Deng; Liangqing Zhang; Yin Cai; Chi Wai Cheung; Zhengyuan Xia
Journal:  J Gen Intern Med       Date:  2020-03-04       Impact factor: 5.128

7.  Age-related rhesus macaque models of COVID-19.

Authors:  Pin Yu; Feifei Qi; Yanfeng Xu; Fengdi Li; Peipei Liu; Jiayi Liu; Linlin Bao; Wei Deng; Hong Gao; Zhiguang Xiang; Chong Xiao; Qi Lv; Shuran Gong; Jiangning Liu; Zhiqi Song; Yajin Qu; Jing Xue; Qiang Wei; Mingya Liu; Guanpeng Wang; Shunyi Wang; Haisheng Yu; Xing Liu; Baoying Huang; Wenling Wang; Li Zhao; Huijuan Wang; Fei Ye; Weimin Zhou; Wei Zhen; Jun Han; Guizhen Wu; Qi Jin; Jianwei Wang; Wenjie Tan; Chuan Qin
Journal:  Animal Model Exp Med       Date:  2020-03-30

8.  A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.

Authors:  Ahmed O Hassan; James Brett Case; Emma S Winkler; Larissa B Thackray; Natasha M Kafai; Adam L Bailey; Broc T McCune; Julie M Fox; Rita E Chen; Wafaa B Alsoussi; Jackson S Turner; Aaron J Schmitz; Tingting Lei; Swathi Shrihari; Shamus P Keeler; Daved H Fremont; Suellen Greco; Paul B McCray; Stanley Perlman; Michael J Holtzman; Ali H Ellebedy; Michael S Diamond
Journal:  Cell       Date:  2020-06-10       Impact factor: 66.850

9.  A Mouse Model of SARS-CoV-2 Infection and Pathogenesis.

Authors:  Shi-Hui Sun; Qi Chen; Hong-Jing Gu; Guan Yang; Yan-Xiao Wang; Xing-Yao Huang; Su-Su Liu; Na-Na Zhang; Xiao-Feng Li; Rui Xiong; Yan Guo; Yong-Qiang Deng; Wei-Jin Huang; Quan Liu; Quan-Ming Liu; Yue-Lei Shen; Yong Zhou; Xiao Yang; Tong-Yan Zhao; Chang-Fa Fan; Yu-Sen Zhou; Cheng-Feng Qin; You-Chun Wang
Journal:  Cell Host Microbe       Date:  2020-05-27       Impact factor: 21.023

10.  Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.

Authors:  Vincent J Munster; Friederike Feldmann; Brandi N Williamson; Neeltje van Doremalen; Lizzette Pérez-Pérez; Jonathan Schulz; Kimberly Meade-White; Atsushi Okumura; Julie Callison; Beniah Brumbaugh; Victoria A Avanzato; Rebecca Rosenke; Patrick W Hanley; Greg Saturday; Dana Scott; Elizabeth R Fischer; Emmie de Wit
Journal:  Nature       Date:  2020-05-12       Impact factor: 49.962

View more
  88 in total

1.  Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-CoV-2.

Authors:  Julia Port; Claude Kwe Yinda; Victoria Avanzato; Jonathan Schulz; Myndi Holbrook; Neeltje van Doremalen; Carl Shaia; Robert Fischer; Vincent Munster
Journal:  Res Sq       Date:  2021-08-09

Review 2.  Cellular mechanisms underlying neurological/neuropsychiatric manifestations of COVID-19.

Authors:  Brittany Bodnar; Kena Patel; Wenzhe Ho; Jin Jun Luo; Wenhui Hu
Journal:  J Med Virol       Date:  2020-12-23       Impact factor: 2.327

3.  Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model.

Authors:  C Joaquín Cáceres; Stivalis Cardenas-Garcia; Silvia Carnaccini; Brittany Seibert; Daniela S Rajao; Jun Wang; Daniel R Perez
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.996

4.  A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses.

Authors:  Alberto A Amarilla; Julian D J Sng; Rhys Parry; Joshua M Deerain; James R Potter; Yin Xiang Setoh; Daniel J Rawle; Thuy T Le; Naphak Modhiran; Xiaohui Wang; Nias Y G Peng; Francisco J Torres; Alyssa Pyke; Jessica J Harrison; Morgan E Freney; Benjamin Liang; Christopher L D McMillan; Stacey T M Cheung; Darwin J Da Costa Guevara; Joshua M Hardy; Mark Bettington; David A Muller; Fasséli Coulibaly; Frederick Moore; Roy A Hall; Paul R Young; Jason M Mackenzie; Jody Hobson-Peters; Andreas Suhrbier; Daniel Watterson; Alexander A Khromykh
Journal:  Nat Commun       Date:  2021-06-08       Impact factor: 14.919

5.  Western diet increases COVID-19 disease severity in the Syrian hamster.

Authors:  Julia R Port; Danielle R Adney; Benjamin Schwarz; Jonathan E Schulz; Daniel E Sturdevant; Brian J Smith; Victoria A Avanzato; Myndi G Holbrook; Jyothi N Purushotham; Kaitlin A Stromberg; Ian Leighton; Catharine M Bosio; Carl Shaia; Vincent J Munster
Journal:  bioRxiv       Date:  2021-06-17

6.  An intranasal vaccine durably protects against SARS-CoV-2 variants in mice.

Authors:  Ahmed O Hassan; Swathi Shrihari; Matthew J Gorman; Baoling Ying; Dansu Yuan; Saravanan Raju; Rita E Chen; Igor P Dmitriev; Elena Kashentseva; Lucas J Adams; Colin Mann; Meredith E Davis-Gardner; Mehul S Suthar; Pei-Yong Shi; Erica Ollmann Saphire; Daved H Fremont; David T Curiel; Galit Alter; Michael S Diamond
Journal:  Cell Rep       Date:  2021-07-10       Impact factor: 9.995

7.  A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.

Authors:  Esther S Gan; Ayesa Syenina; Martin Linster; Benson Ng; Summer L Zhang; Satoru Watanabe; Ravisankar Rajarethinam; Hwee Cheng Tan; Gavin Jd Smith; Eng Eong Ooi
Journal:  Antiviral Res       Date:  2021-07-08       Impact factor: 5.970

Review 8.  COVID-19: Lung-Centric Immunothrombosis.

Authors:  Peter R Kvietys; Hana M A Fakhoury; Sana Kadan; Ahmed Yaqinuddin; Eid Al-Mutairy; Khaled Al-Kattan
Journal:  Front Cell Infect Microbiol       Date:  2021-06-11       Impact factor: 5.293

9.  Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-CoV-2.

Authors:  Julia R Port; Claude Kwe Yinda; Victoria A Avanzato; Jonathan E Schulz; Myndi G Holbrook; Neeltje van Doremalen; Carl Shaia; Robert J Fischer; Vincent J Munster
Journal:  bioRxiv       Date:  2021-07-26

Review 10.  Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions.

Authors:  Marcel Renn; Eva Bartok; Thomas Zillinger; Gunther Hartmann; Rayk Behrendt
Journal:  Pharmacol Ther       Date:  2021-06-23       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.